Case ascertainment and estimated incidence of drug-induced long-QT syndrome: study in Southwest France.
OBJECTIVE
The aim of this study was to investigate the incidence and reporting rate of drug-induced long-QT syndrome (LQTS) in France [defined by evidence of torsades de pointes (TdP), QT prolongation and exposure to a relevant drug] and to assess feasibility of case collection for drug-induced LQTS.


METHODS
A retrospective population-based study was carried out in Southwest France in five institutions: three main hospitals, one private clinic and one cardiac emergency unit, searched from 1 January 1999 to 1 January 2005 (population coverage of 614 000). The study population consisted of 861 cases with International Classification of Diseases-10 diagnostic codes for ventricular tachycardia (I147.2), ventricular fibrillation (I149.0) and sudden cardiac death (I146.1) from hospital discharge summaries, supplemented by cases reported to national or regional pharmacovigilance systems, and voluntary reporting by physicians, validated according to internationally defined criteria for drug-induced LQTS.


RESULTS
Of 861 patients coded with arrhythmias or sudden cardiac death, there were 40 confirmed surviving acquired cases of drug-induced LQTS. We estimated that the incidence of those who survive to reach hospital drug-induced LQTS is approximately 10.9 per million annually in France (95% confidence interval 7.8, 14.8).


CONCLUSIONS
Many cases of drug-induced LQTS may not survive before they reach hospital, as the reporting rate for drug-induced LQTS identified through the cardiology records and also reported to pharmacovigilance systems for the Midi-Pyrenees area is 3/40 (7.5%). Using the methods outlined it is possible to assemble cases to study genetic susceptibility to drug-induced LQTS and adapt these methods more widely.
Molokhia
Mariam
M
Non-Communicable Disease Epidemiology UnitLondon School of Hygiene & Tropical MedicineKeppel Street, WC1E 7HT London, UK. mariam.molokhia@lshtm.ac.uk
Pathak
Atul
A
Lapeyre-Mestre
Maryse
M
Caturla
Laetitia
L
Montastruc
Jean Louis
JL
McKeigue
Paul
P
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000139:chemically induced*; D016757:Death, Sudden, Cardiac / Q000453:epidemiology; D004562:Electrocardiography; D005240:Feasibility Studies; D005260:Female; D005602:France; D020022:Genetic Predisposition to Disease; D006801:Humans; D015994:Incidence; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000453:epidemiology / Q000235:genetics; D008297:Male; D008875:Middle Aged; D015221:Potassium Channels; D012189:Retrospective Studies; D012307:Risk Factors; D016171:Torsades de Pointes / Q000139:chemically induced* / Q000453:epidemiology / Q000235:genetics
D000889:Anti-Arrhythmia Agents; D015221:Potassium Channels